The price of medical drugs in Switzerland remains higher than in other major European markets, especially for generic drugs, which are almost twice as expensive. Patented drugs also cost more.
The reason for the increased price difference for patent-protected medicines is the exchange rate, said Santésuisse and Interpharma, umbrella organisations for Swiss insurers and pharmaceutical research companies, on Thursday.
At an exchange rate of CHF1.11 per euro, the 250 top-selling patented drugs were 6.9% more expensive in Switzerland in spring 2021 than in comparable foreign countries. A year ago the same medicines were only 4.5% more expensive.
The price difference for 250 patent-expired original drugs also increased, to 11.5% from 10% in 2020. However, the price difference remains by far the greatest for generics. On average, these cost 45% more in Switzerland, compared with 42% more in the previous year.
“Unfortunately the premium payers felt the increased price differences […] very directly: in Switzerland we pay over CHF200 million ($222 million) more for patent-protected medicines than in the comparable countries,” said Verena Nold, director of Santésuisse, in a statementExternal link.
Reference price system
Nold is therefore once again calling for the reference price system, which establishes a common reimbursement level or reference price for a group of interchangeable medicines. This could save the local premium payers several hundred million francs a year, she said.
“Parliament still has time this year to show its colours and stand up for the premium payers,” she said.
The price comparison was carried out for the 12th time. It compared the ex-factory prices in Switzerland with those in Belgium, Denmark, Germany, Finland, France, the United Kingdom, the Netherlands, Austria and Sweden for patented and off-patent medicines and generics.
Popular Stories
More
Life & Aging
Why liberal Switzerland is opposed to the Sarco suicide capsule
Swiss railways keep breaking passenger traffic records
This content was published on
Following a record in the first quarter, the railways set a new second-quarter record in 2024 with 5.78 billion passenger-kilometres between April and June.
Rents in Switzerland continue to climb as housing shortage persists
This content was published on
Rents in Switzerland continue to rise, a trend further accentuated by stagnant construction activity and population growth.
Swiss scientists develop new method for measuring permafrost
This content was published on
Scientists in Fribourg have developed a new method to measure permafrost, potentially enhancing predictions of rockfalls and landslides.
Italian mountaineer dies after rockfall on the Matterhorn
This content was published on
The man wanted to climb the 4,478-metre peak in canton Valais via the Hörnligrat ridge with a companion as part of a two-man rope team.
This content was published on
Banque Havilland SA, a private bank owned by the family of close friends of Prince Andrew, has begun the process of closing its operations in Switzerland.
Swiss pharmacies face Covid-19 vaccine shortages amid summer wave
This content was published on
Switzerland is facing a summer wave of Covid-19, with pharmacies and doctors’ surgeries struggling with vaccine shortages.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Drug prices fall in Switzerland but generics remain expensive
This content was published on
Switzerland is narrowing the gap with other European countries when it comes to the cost of medicines. But generics are still double the price.
Costs of generic drugs and outpatient services targeted
This content was published on
The government wants to cap prices for generic drugs as part of a package of measures to reduce rising health costs in Switzerland.
This content was published on
Switzerland could save millions of francs by prescribing low-priced biotech drug copies, known as biosimilars, instead of expensive biologicals.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.